Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swedish Orphan Biovitrum AB ( (SE:SOBI) ) has shared an announcement.
Swedish Orphan Biovitrum AB (Sobi) has announced its acquisition of Arthrosi Therapeutics, a biotechnology company specializing in next-generation treatments for gout. This strategic move enhances Sobi’s pipeline with pozdeutinurad, a promising Phase 3 URAT1 inhibitor, which could significantly boost Sobi’s growth and market position in the gout treatment sector. The acquisition, valued at up to USD 1.5 billion, is expected to close in the first half of 2026 and will be primarily funded through debt. This deal underscores Sobi’s commitment to expanding its treatment options for gout and is anticipated to be highly accretive to the company’s long-term growth and margins.
The most recent analyst rating on (SE:SOBI) stock is a Hold with a SEK374.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a biopharmaceutical company based in Stockholm, Sweden, specializing in the development and commercialization of treatments for rare diseases. The company focuses on providing innovative therapies in areas such as hematology, immunology, and specialty care, with a strong emphasis on addressing unmet medical needs.
Average Trading Volume: 393,547
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK114.8B
For detailed information about SOBI stock, go to TipRanks’ Stock Analysis page.